TNFAIP2 Biomarker Detection for Early Atherosclerosis Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for atherosclerosis, such as angiography and traditional biomarkers, are invasive, expensive, or lack sensitivity for early-stage detection, making it difficult to accurately identify and monitor the progression of the disease.
Innovation Solution
Utilizing Yes-associated protein (YAP)-induced secretory protein TNFAIP2 as a biomarker, which is highly expressed in vascular endothelia and sera of subjects with atherosclerosis, allowing for non-invasive detection and monitoring through methods like ELISA assays using anti-TNFAIP2 antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If angiography is used for diagnosis of atherosclerotic vascular disease, then diagnostic accuracy is improved, but invasiveness and risk of complications increase
Solution Approach 1:
The patent uses TNFAIP2 as an intermediary biomarker that indirectly indicates the presence and progression of atherosclerosis. Instead of directly visualizing blood vessels through invasive angiography, the method measures TNFAIP2 levels in blood samples, which serve as a mediator reflecting endothelial cell stress and plaque burden. This intermediary approach maintains diagnostic accuracy while eliminating the harms of invasive procedures.
2Ease of operation
If traditional biomarkers (cholesterol, LDL, triglycerides) are used for diagnosis, then ease of measurement is improved, but diagnostic accuracy for early-stage atherosclerosis deteriorates
Solution Approach 1:
The patent shifts the diagnostic parameter from traditional lipid markers (cholesterol, LDL, triglycerides) to a novel parameter - TNFAIP2 protein levels. This parameter change enables early detection of atherosclerosis by measuring endothelial stress responses before significant plaque formation occurs, while maintaining ease of measurement through standard ELISA or mass spectrometry techniques.
3Measurement precision
If inflammatory biomarkers (interleukin 6, C-reactive protein) are used for diagnosis, then sensitivity to inflammation is improved, but specificity for atherosclerosis deteriorates
Solution Approach 1:
The patent applies local quality by focusing on a specific biomarker (TNFAIP2) produced locally by vascular endothelial cells in response to atherosclerotic stress. Unlike systemic inflammatory markers that reflect general inflammation anywhere in the body, TNFAIP2 is specifically produced at the site of endothelial injury and plaque formation, providing both sensitivity to inflammation and specificity for atherosclerosis through its localized production pattern.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a sensitive and reliable method for diagnosing, prognosing, and monitoring atherosclerosis, enabling early detection and treatment, thereby reducing the risk of cardiovascular events.
Implementation Method 1
measuring the TNFAIP2 level in a biological sample from the subject using an anti-TNFAIP2 antibody or a TNFAIP2 binding molecule
Data Source
AI summary
The current disclosure provides sensitive diagnostic methods that do not require invasive angiography. It was found that TNFAIP2 was secreted into the sera of subjects with atherosclerosis. This novel biomarker can be used to detect early-stage atherosclerosis. Accordingly, aspects of the disclosure relate to a method for measuring a TNFAIP2 level comprising: obtaining a biological sample from a subject having, suspected of having, or at risk of having atherosclerosis; and measuring the TNFAIP2 level in a biological sample from the subject as compared to a control. Also disclosed is a method for treating or preventing atherosclerosis in a subject, the method comprising administering an effective amount of a treatment for atherosclerosis to the subject after measuring the TNFAIP2 level in a biological sample from the subject as compared to a control.